Clinical trials / NCT04286607
NCT04286607Phase 3Completed

Open-Label Extension Trial of PDE4 Inhibition With Roflumilast for the Management of Plaque Psoriasis

Study sponsor: Arcutis Biotherapeutics, Inc. · ARQT

Compare the available registry edits below. Primary completion is the date data collection ends for the main study measures; it does not tell you when results will be published.

Open ClinicalTrials.gov recordCSV export · Pro
Primary completion2024-01-22Actual
Enrollment · participants337Actual
Source updated2026-09-09Last update listed in the registry record
Version history

Changes to this trial

Last 12 months
Pro unlocks the full available history and CSV export. View Pro features

· 2 fields changed

Main study measure wording changed

Text changed; whether the study measures changed has not been verified. Saved text may be shortened.

Compare wording
− Before

Measure: Occurrence of treatment emergent AEs (TEAEs)

+ After

Measure: Percentage of Participants With ≥1 Treatment-Emergent Adverse Events (TEAEs) Measure: Percentage of Participants With ≥1 Serious Adverse Events (SAEs)

Actual enrollment increased by 4 participants

− Before

333 participants (actual)

+ After

337 participants (actual)

Check registry source